In angiotensin-converting enzyme inhibitor-intolerant individuals, the angiotensin receptor blocker telmisartan does not reduce the incidence of major cardiovascular events in high-risk patients: lessons learned from the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects Wtih Cardiovascular Disease (TRANSCEND)

对于血管紧张素转换酶抑制剂不耐受的个体，血管紧张素受体阻滞剂替米沙坦并不能降低高危患者发生重大心血管事件的概率：从血管紧张素转换酶抑制剂不耐受心血管疾病患者的替米沙坦随机评估研究（TRANSCEND）中吸取的教训